Literature DB >> 26451721

Clinical characteristics and abandonment and outcome of treatment in 67 Chinese children with medulloblastoma.

Chen Wang1, Xiao-Jun Yuan1, Ma-Wei Jiang2, Li-Feng Wang3.   

Abstract

OBJECT The purpose of this study was to explore the clinical features and outcome of medulloblastoma in Chinese children. The authors analyze the reasons that treatment is abandoned and attempt to provide evidence-based recommendations for improving the prognosis of medulloblastoma in this population. METHODS A total of 67 pediatric cases of newly diagnosed medulloblastoma were included in this study. All of the children were treated at Xinhua Hospital between January 2007 and June 2013. The authors retrospectively analyzed the clinical data, treatment modalities, and outcome. The male-to-female ratio was 2:1, and the patients' median age at diagnosis was 51.96 months (range 3.96-168.24 months). The median duration of follow-up was 32 months (range 3-70 months). RESULTS At the most recent follow-up date, 31 patients (46%) were alive, 30 (45%) had died, and 6 (9%) had been lost to follow-up. The estimated 3-year overall survival and progression-free survival, based on Kaplan-Meier analysis, were 55.1% ± 6.4% and 45.6% ± 6.7%, respectively. Univariate analysis showed that standard-risk group (p = 0.009), postoperative radiotherapy (RT) combined with chemotherapy (p < 0.001), older age (≥ 3 years) at diagnosis (p = 0.010), gross-total resection (p = 0.012), annual family income higher than $3000 (p = 0.033), and living in urban areas (p = 0.008) were favorable prognostic factors. Multivariate analysis revealed that postoperative RT combined with chemotherapy was an independent prognostic factor (p < 0.001). The treatment abandonment rate in this cohort was 31% (21 of 67 cases). CONCLUSIONS There was a large gap between the outcome of medulloblastoma in Chinese children and the outcome in Western children. Based on our data, treatment abandonment was the major cause of therapeutic failure. Parents' misunderstanding of medulloblastoma played a major role in abandonment, followed by financial and transportation difficulties. Establishment of multidisciplinary treatment teams could improve the prognosis of medulloblastoma in Chinese children.

Entities:  

Keywords:  Chinese children; GTR = gross-total resection; OS = overall survival; PFS = progression-free survival; RT = radiotherapy; STR = subtotal resection; clinical characteristic; medulloblastoma; oncology; prognosis

Mesh:

Year:  2015        PMID: 26451721     DOI: 10.3171/2015.5.PEDS1573

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  4 in total

Review 1.  The clinical importance of medulloblastoma extent of resection: a systematic review.

Authors:  Eric M Thompson; Alexa Bramall; James E Herndon; Michael D Taylor; Vijay Ramaswamy
Journal:  J Neurooncol       Date:  2018-05-23       Impact factor: 4.130

2.  Clinicopathological features and microsurgical outcomes for giant pediatric intracranial tumor in 60 consecutive cases.

Authors:  Ailing Guo; Vigneyshwar Suresh; Xianzhi Liu; Fuyou Guo
Journal:  Childs Nerv Syst       Date:  2017-02-08       Impact factor: 1.475

3.  Risk Factors Associated with Post-therapeutic Outcome for Medulloblastoma: An Experience from Indonesia.

Authors:  David Tandian; Alphadenti Harlyjoy; Setyo Widi Nugroho; Syaiful Ichwan
Journal:  Asian J Neurosurg       Date:  2021-09-14

4.  Treatment barriers and clinical outcome of children with medulloblastoma in China: a report from the Chinese Children's Cancer Group (CCCG).

Authors:  Anthony Pak-Yin Liu; Zijun Zhen; Qunying Yang; Xiaojun Yuan; Xiaoli Ma; Jianliang Chen; Jingsheng Wang; Lihua Yang; Haixia Guo; Lian Jiang; Wenjun Weng; Libin Huang; Wei Liu; Jian Wang; Shaoxiong Wu; Jing Zeng; Mawei Jiang; Kejun He; Ming Ge; Kevin King-Fai Cheng; Wilson Wai-Shing Ho; Chunyu Li; Lihua Yu; Shuai Zhu; Ho-Keung Ng; Godfrey Chi-Fung Chan; Xiaofei Sun
Journal:  Neurooncol Adv       Date:  2021-09-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.